BioCentury | Jul 10, 2020
Politics, Policy & Law

Democrats, Republicans could find common ground on drug pricing recommendations from Biden-Sanders task force

Recommendations from a task force assembled by Joe Biden and Sen. Bernie Sanders (I-Vt.) include several healthcare policies favored by Democrats, like Medicare drug price negotiation, but stop short of Medicare for All. The bulk...
BioCentury | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

Robust local demand helped Ascentage to price its IPO at the top of its proposed range and its shares to rise out of the gate in the second offering after a four-month lapse in listings...
BioCentury | Oct 24, 2019
Financial News

Oct. 23 Financial Quick Takes: Alexion buyback; plus RAPT, NeuroRX and Oyster Point

Billion-dollar buyback for Alexion The board of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) has approved a $1 billion share repurchase authorization, with no expiration date. Alexion announced the buyback with its 3Q19 earnings, in which it reported...
BioCentury | Sep 27, 2019
Financial News

Sept. 27 Financial Quick Takes: Beam hops into IPO queue; plus Amryt, T3, Junshi, Newronika

Beam seeking NASDAQ IPO Beam Therapeutics filed to raise up to $100 million in an IPO underwritten by J.P. Morgan, Jefferies, Barclays and Wedbush PacGrow. The base editing company has 12 preclinical programs across hematology,...
BioCentury | Jun 28, 2019
Politics & Policy

‘Product hopping’ under fire in Senate bill

When Allergan withdrew Alzheimer's disease drug Namenda memantine from the market so physicians would prescribe a reformulated once-daily version with a longer patent life, the company was engaging in an anticompetitive practice, according to Sen....
BioCentury | May 8, 2019
Politics & Policy

May 8 P&P Quick Takes: FTC, Part D, Orange/Purple Book, FDA, Cornyn/Blumenthal

FTC objects to FDA's latest guidance on biologic naming The Federal Trade Commission again advised that FDA drop its biologic suffix naming convention because it could diminish biosimilar competition, bolstering arguments from some biosimilars manufacturers...
BioCentury | Apr 26, 2019
Financial News

CRO Viva could get $749M valuation in Hong Kong listing, Ascentage refiles

Viva would raise HK$1.4 billion ($172.2 million) and be valued at HK$5.9 billion ($748.7 million) if the drug discovery services company prices its Hong Kong IPO at the midpoint of the range it proposed April...
BioCentury | Aug 31, 2018
Financial News

Ascentage hops in Hong Kong IPO queue

Ascentage Pharma Group International (Suzhou, China) proposed Aug. 20 to list on Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by BofA Merrill Lynch and Citi. The biotech's pipeline comprises seven clinical...
BioCentury | Aug 31, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

Mabpharm Ltd. (Taizhou, China) proposed Aug. 22 to list on the Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by CICC. Mabpharm is the second biotechnology company this week to file to...
BioCentury | Aug 22, 2018
Financial News

Biosimilars company Mabpharm sets sights on Hong Kong IPO

Mabpharm Ltd. (Taizhou, China) proposed Wednesday to list on the Hong Kong Exchanges and Clearing Ltd. (HKEX) in an IPO underwritten by CICC. Mabpharm is the second biotechnology company this week to file to list...
Items per page:
1 - 10 of 40